Sign In
Buy AMRX
$12.88
+0.225 (+1.78%)
At Close: Jun 03, 2026
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year?
10:41am, Thursday, 22'nd Jan 2026
Here is how Amneal Pharmaceuticals (AMRX) and Biohaven Ltd. (BHVN) have performed compared to their sector so far this year.
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $13.80 Average PT from Brokerages
01:15am, Thursday, 22'nd Jan 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the five brokerages that are covering the firm, Marketbeat reports. One equi
Short Interest in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Grows By 28.4%
05:00am, Monday, 19'th Jan 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - Get Free Report) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totaling 6,851,192 s
Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock?
10:40am, Thursday, 15'th Jan 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
11:36pm, Tuesday, 13'th Jan 2026
Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
WASHINGTON--(BUSINESS WIRE)--KeifeRx, a privately held biotechnology company developing disease-modifying therapies for neurodegenerative disorders, today announced that it has entered into a research
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Rating of “Moderate Buy” by Analysts
03:16am, Thursday, 25'th Dec 2025
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - Get Free Report) has received a consensus rating of "Moderate Buy" from the five analysts that are currently covering the firm, Marketbeat reports. One inv
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Rating of “Moderate Buy” from Analysts
03:16am, Thursday, 25'th Dec 2025
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five research firms that are covering the company, Marketbeat.com reports. One
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
04:01pm, Monday, 22'nd Dec 2025
BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) and mAbxience, a Fresenius Kabi majority-owned group with partial o
Assenagon Asset Management S.A. Raises Holdings in Amneal Pharmaceuticals, Inc. $AMRX
03:26am, Saturday, 20'th Dec 2025
Assenagon Asset Management S.A. grew its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) by 187.1% in the third quarter, according to the company in its most recent 13F filing with the Securit
Amneal: Growing Drug Portfolio, Positive Cash Flow, Outweighing Leverage Risks
11:01pm, Wednesday, 17'th Dec 2025
Today's article presents why Amneal should get my prior buy rating from September reaffirmed. Although some technical signals support a hold rather than bullishness, fundamental analysis shows several
Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals
04:01pm, Tuesday, 09'th Dec 2025
BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) ha
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson's Disease
08:00am, Friday, 05'th Dec 2025
BRIDGEWATER, N.J., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced new positive interim results from its ongoing Phase
Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol
08:00am, Tuesday, 02'nd Dec 2025
BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) ha
Amneal to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 02'nd Dec 2025
BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, and Tasos Konidaris, Chief Financi
